卵巢刺激中晚卵泡期孕酮升高与解冻周期中染色体筛查胚胎种植率降低无关
这项单中心回顾性队列分析纳入2016年9月至2020年3月共5141个IVF/PGT-A周期和5806个单整倍体冻胚移植周期,比较晚卵泡期孕酮≤2.0 ng/ml与>2.0 ng/ml两组。结果显示两组卵母细胞成熟率、受精率、囊胚形成率、整倍体率及冻胚移植后的种植率、临床妊娠率、持续妊娠率、活产儿出生指标均无显著差异,多因素分析未发现孕酮升高与胚胎非整倍体风险增加相关。
要点
- 晚卵泡期孕酮以2.0 ng/ml为界,升高组与正常组囊胚可利用率和整倍体率无显著差异。
- 多因素分析未发现孕酮升高与胚胎非整倍体风险增加相关(校正OR 1.04,95%CI 0.86-1.27,P=0.62)。
- 单整倍体冻胚移植后两组种植率、临床妊娠率、持续妊娠率及活产儿出生指标均无显著差异。
核心结论
- 晚卵泡期孕酮升高(以2.0 ng/ml为界)与胚胎发育受损、非整倍体率增加及整倍体冻胚移植后种植和妊娠结局受损均无关。
研究设计与样本
- 单一生殖医学学术中心自2016年9月至2020年3月的回顾性队列分析,共分析5244个IVF/PGT-A控制性卵巢过度刺激周期,其中5141个纳入分析。
- 共23991个囊胚接受滋养层活检和PGT分析,并评估5806个单整倍体冻胚移植周期的临床结局。
主要发现
- 可利用囊胚率在孕酮正常组为65.3%(n=22654),孕酮升高组为62.4%(n=1337),差异无统计学意义(P=0.19)。
- 整倍体率分别为52.8%(n=11964)和53.4%(n=714),差异无统计学意义(P=0.81)。
- 多因素分析采用广义估计方程,未发现晚卵泡期孕酮升高与胚胎非整倍体风险增加相关(校正OR 1.04,95%CI 0.86-1.27,P=0.62)。
- 5806个整倍体冻胚移植周期中,孕酮正常组5617个周期与升高组189个周期在移植优质胚胎数、种植率、临床妊娠率、持续妊娠率、多胎妊娠率和临床妊娠丢失率方面相当;活产儿中两组孕周(39.0±1.89 vs 39.24±1.53,P=0.25)和出生体重(3317±571.9 g vs 3266±455.8 g,P=0.26)无显著差异。
关键数值与推荐
- 晚卵泡期孕酮升高的截断值定义为2.0 ng/ml。
- 第1组为扳机日孕酮正常(P≤2.0 ng/ml)周期获取的卵母细胞,第2组为晚卵泡期孕酮升高(P>2.0 ng/ml)周期获取的卵母细胞。
- 整倍体冻胚移植周期中,孕酮正常组与升高组在患者BMI、抗苗勒管激素、移植日子宫内膜厚度和既往IVF周期数方面无差异,但患者年龄和卵母细胞年龄存在显著差异。
临床怎么用
- 作者结论认为,晚卵泡期孕酮升高不预测胚胎发育潜能,来自孕酮升高周期的胚胎可用于移植。
- 作者认为可告知患者,其获得健康妊娠的几率与暴露于生理正常孕酮水平的周期所获胚胎相似。
局限性
- 研究的回顾性性质可能限制外部真实性。
- 研究中心的实验室方案可能存在变异,所选孕酮截断值和孕酮检测技术与其他辅助生殖中心相比可能存在差异,可能限制外部真实性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the impact of a late follicular phase progesterone elevation (LFPE) during controlled ovarian hyperstimulation (COH) on embryonic competence and reproductive potential in thaw cycles of preimplantation genetic testing for aneuploidy (PGT-A) screened embryos? SUMMARY ANSWER: Our study findings suggest that LFPE, utilizing a progesterone cutoff value of 2.0 ng/ml, is neither associated with impaired embryonic development, increased rate of embryonic aneuploidy, nor compromised implantation and pregnancy outcomes following a euploid frozen embryo transfer (FET) cycle. WHAT IS KNOWN ALREADY: Premature progesterone elevation during COH has been associated with lower pregnancy rates due to altered endometrial receptivity in fresh IVF cycles. Also, increased levels of progesterone (P) have been suggested to be a marker for ovarian dysfunction, with some evidence to show an association between LFPE and suboptimal embryonic development. However, the effect of LFPE on embryonic competence is still controversial. STUDY DESIGN, SIZE, DURATION: Retrospective cohort analysis in a single, academic ART center from September 2016 to March 2020. In total, 5244 COH cycles for IVF/PGT-A were analyzed, of those 5141 were included in the analysis. A total of 23 991 blastocysts underwent trophectoderm biopsy and PGT analysis. Additionally, the clinical IVF outcomes of 5806 single euploid FET cycles were evaluated. PARTICIPANTS/MATERIALS, SETTING, METHODS: Cohorts were separated in two groups: Group 1: oocytes retrieved from cycles with normal P levels during ovulation trigger (P ≤ 2.0 ng/ml); Group 2: oocytes retrieved after cycles in which LFPE was noted (P > 2.0 ng/ml). Extended culture and PGT-A was performed. Secondly, IVF outcomes after a single euploid FET were evaluated for each cohort. MAIN RESULTS AND THE ROLE OF CHANCE: Four thousand nine hundred and twenty-five cycles in Group 1 were compared with 216 cycles on Group 2. Oocyte maturity rates, fertilization rates and blastulation rates were comparable among groups. A 65.3% (n = 22 654) rate of utilizable blastocysts was found in patients with normal P levels and were comparable to the 62.4% (n = 1337) observed in those with LFPE (P = 0.19). The euploidy rates were 52.8% (n = 11 964) and 53.4% (n = 714), respectively, albeit this difference was not statistically significant (P = 0.81). Our multivariate analysis was fitted with a generalized estimating equation (GEE) and no association was found with LFPE and an increased odds of embryo aneuploidy (adjusted odds ratio 1.04 95% CI 0.86-1.27, P = 0.62). A sub-analysis of subsequent 5806 euploid FET cycles (normal P: n = 5617 cycles and elevated P: n = 189 cycles) showed no differences among groups in patient's BMI, Anti-Müllerian hormone (AMH), endometrial thickness at FET and number of prior IVF cycles. However, a significant difference was found in patient's age and oocyte age. The number of good quality embryos transferred, implantation rate, clinical pregnancy rate, ongoing pregnancy rate, multiple pregnancy rate and clinical pregnancy loss rates were comparable among groups. Of the registered live births (normal P group: n = 2198; elevated P group: n = 52), there were no significant differences in gestational age weeks (39.0 ± 1.89 versus 39.24 ± 1.53, P = 0.25) and birth weight (3317 ± 571.9 versus 3 266 ± 455.8 g, P = 0.26) at delivery, respectively. LIMITATIONS, REASONS FOR CAUTION: The retrospective nature of the study and probable variability in the study center's laboratory protocol(s), selected progesterone cutoff value and progesterone assay techniques compared to other ART centers may limit the external validity of our findings. WIDER IMPLICATIONS OF THE FINDINGS: Based on robust sequencing data from a large cohort of embryos, we conclude that premature P elevation during IVF stimulation does not predict embryonic competence. Our study results show that LFPE is neither associated with impaired embryonic development nor increased rates of aneuploidy. Embryos obtained from cycles with LFPE can be selected for transfer, and patients can be reassured that the odds of achieving a healthy pregnancy are similar to the embryos exposed during COH cycles to physiologically normal P levels. STUDY FUNDING/COMPETING INTEREST(S): No funding was received for the realization of this study. Dr A.B.C. is advisor and/or board member of Sema 4 (Stakeholder in data), Progyny and Celmatix. The other authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: NA.
引用
- Hernandez-Nieto C, Lee JA, Alkon-Meadows T, et al. Late follicular phase progesterone elevation during ovarian stimulation is not associated with decreased implantation of chromosomally screened embryos in thaw cycles. Hum Reprod. 2020. PMID: 32649755. doi:10.1093/humrep/deaa123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。